NEJM:KRAS激活突变导致脑动静脉畸形

2018-01-04 zhangfan MedSci原创

研究发现脑动静脉畸形组织样本中存在KRAS激活突变,提示上述畸形是由KRAS诱导的脑内皮细胞MAPK-Erk信号通路激活所致

脑内零星动静脉畸形是指脑血管中动脉和静脉之间形态上的异常连接,是导致年轻人和儿童出血性中风的主要原因,目前造成这种罕见局灶性病症的遗传因素尚不清楚。

近日研究人员对脑动静脉畸形患者的组织和血液样本进行体细胞突变研究。对参与者样本进行PCR分析,考察激活KRAS突变而引起的下游信号通路、基因表达和细胞表型的变化。

研究发现62.5%的患者组织样本中存在体细胞激活KRAS突变,但血液样本无变化。对脑动静脉畸形内皮细胞培养后,内皮细胞中检测到KRAS突变并观察到突变KRAS表达(KRASG12V),突变诱导细胞外信号调节激酶活性增强、与血管生成和Notch信号有关的基因表达增加,迁移行为增强,上述过程可以被MAPK-ERK信号抑制剂所抑制。

研究发现脑动静脉畸形组织样本中存在KRAS激活突变,提示上述畸形是由KRAS诱导的脑内皮细胞MAPK-Erk信号通路激活所致。

原始出处:

Sergey I. Nikolaev et al. Somatic Activating KRAS Mutations in Arteriovenous Malformations of the Brain. N Engl J Med. January 4, 2018.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1697610, encodeId=3676169e610ed, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Sun Dec 16 19:29:00 CST 2018, time=2018-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1642136, encodeId=87fc16421365e, content=<a href='/topic/show?id=5070333625b' target=_blank style='color:#2F92EE;'>#动静脉畸形#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33362, encryptionId=5070333625b, topicName=动静脉畸形)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=46c022864035, createdName=12498cf9m42(暂无昵称), createdTime=Fri May 04 23:29:00 CST 2018, time=2018-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1362206, encodeId=37dc13622064c, content=<a href='/topic/show?id=9857e03444b' target=_blank style='color:#2F92EE;'>#畸形#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70344, encryptionId=9857e03444b, topicName=畸形)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Sat Jan 06 00:29:00 CST 2018, time=2018-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1368996, encodeId=96231368996e7, content=<a href='/topic/show?id=13cb1056e20' target=_blank style='color:#2F92EE;'>#KRAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10567, encryptionId=13cb1056e20, topicName=KRAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Sat Jan 06 00:29:00 CST 2018, time=2018-01-06, status=1, ipAttribution=)]
    2018-12-16 fusion
  2. [GetPortalCommentsPageByObjectIdResponse(id=1697610, encodeId=3676169e610ed, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Sun Dec 16 19:29:00 CST 2018, time=2018-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1642136, encodeId=87fc16421365e, content=<a href='/topic/show?id=5070333625b' target=_blank style='color:#2F92EE;'>#动静脉畸形#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33362, encryptionId=5070333625b, topicName=动静脉畸形)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=46c022864035, createdName=12498cf9m42(暂无昵称), createdTime=Fri May 04 23:29:00 CST 2018, time=2018-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1362206, encodeId=37dc13622064c, content=<a href='/topic/show?id=9857e03444b' target=_blank style='color:#2F92EE;'>#畸形#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70344, encryptionId=9857e03444b, topicName=畸形)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Sat Jan 06 00:29:00 CST 2018, time=2018-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1368996, encodeId=96231368996e7, content=<a href='/topic/show?id=13cb1056e20' target=_blank style='color:#2F92EE;'>#KRAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10567, encryptionId=13cb1056e20, topicName=KRAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Sat Jan 06 00:29:00 CST 2018, time=2018-01-06, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1697610, encodeId=3676169e610ed, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Sun Dec 16 19:29:00 CST 2018, time=2018-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1642136, encodeId=87fc16421365e, content=<a href='/topic/show?id=5070333625b' target=_blank style='color:#2F92EE;'>#动静脉畸形#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33362, encryptionId=5070333625b, topicName=动静脉畸形)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=46c022864035, createdName=12498cf9m42(暂无昵称), createdTime=Fri May 04 23:29:00 CST 2018, time=2018-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1362206, encodeId=37dc13622064c, content=<a href='/topic/show?id=9857e03444b' target=_blank style='color:#2F92EE;'>#畸形#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70344, encryptionId=9857e03444b, topicName=畸形)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Sat Jan 06 00:29:00 CST 2018, time=2018-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1368996, encodeId=96231368996e7, content=<a href='/topic/show?id=13cb1056e20' target=_blank style='color:#2F92EE;'>#KRAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10567, encryptionId=13cb1056e20, topicName=KRAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Sat Jan 06 00:29:00 CST 2018, time=2018-01-06, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1697610, encodeId=3676169e610ed, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Sun Dec 16 19:29:00 CST 2018, time=2018-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1642136, encodeId=87fc16421365e, content=<a href='/topic/show?id=5070333625b' target=_blank style='color:#2F92EE;'>#动静脉畸形#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33362, encryptionId=5070333625b, topicName=动静脉畸形)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=46c022864035, createdName=12498cf9m42(暂无昵称), createdTime=Fri May 04 23:29:00 CST 2018, time=2018-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1362206, encodeId=37dc13622064c, content=<a href='/topic/show?id=9857e03444b' target=_blank style='color:#2F92EE;'>#畸形#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70344, encryptionId=9857e03444b, topicName=畸形)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Sat Jan 06 00:29:00 CST 2018, time=2018-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1368996, encodeId=96231368996e7, content=<a href='/topic/show?id=13cb1056e20' target=_blank style='color:#2F92EE;'>#KRAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10567, encryptionId=13cb1056e20, topicName=KRAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Sat Jan 06 00:29:00 CST 2018, time=2018-01-06, status=1, ipAttribution=)]
    2018-01-06 yinhl1978

相关资讯

Stroke:2017AHA/ASA脑动静脉畸形管理科学声明

自从2001年AHA公布了脑动静脉畸形(bAVM)的声明后,bAVM的自然史和治疗结局等研究都取得了很大进展,特别是首个未破裂bAVM的随机对照试验ARUBA研究发表后bAVM的声明急需更新。

J Neurosurg:如何处理高级别脑动静脉畸形?

目前,脑动静脉畸形(AVM)的治疗主要是血管内栓塞、显微手术切除、立体定向放疗(SRS)和随访观察等几种手段的综合治疗。对于高级别的,即Spetzler-Martin分级在III至V级的AVM,其体积大、部位深或累及功能区,单纯手术切除风险很大。单次SRS的总放射剂量低,不适合用于高级别AVM。体积分割SRS(VS-SRS)将AVM畸形团分割为2-3个部分进行放疗,可以达到更高的放射剂量,但治愈率

JAMA:未破裂的脑动静脉畸形保守治疗或介入治疗后的转归

对于未破裂的脑动静脉畸形(bAVMs),由于缺乏长期的比较数据,保守治疗是否优于介入治疗尚不清楚。来自英国爱丁堡市爱丁堡大学临床脑科学中心临床神经分部的鲁斯塔姆·阿勒沙希·萨洛曼等博士考察比较了bAVMs保守治疗与介入治疗的长期转归。 设计、场所和参与者 对204名年龄≥16岁的居民进行了基于人群的起始队列研究,他们均于1999-2003年或2006-2010年期间首次被确诊为未破裂的bAVMs

Stroke:脑动静脉畸形与静脉内膜增生有关

由此可见,最大静脉管壁厚度增加与较高的大脑动静脉畸形总流量和每引流静脉大脑动静脉畸形流量有关。这一发现表明在静脉内膜增生中有长期较高的大脑动静脉畸形血流流入。

大型脑动静脉畸形的栓塞策略和技巧

由于缺乏理想的栓塞材料,血管内治疗脑动静脉畸形(AVM)的治愈率一直较低。氰基丙烯酸正丁酯(NBCA)有粘管的危险性,不能长时间注射,因此对于大型脑AVM栓塞疗效很不理想。 近年来,新型液态栓塞剂Onyx应用于临床,使脑AVM的栓塞疗效明显提高。Onyx不易与微导管粘连,可以长时间缓慢注射,且弥散性和可控性较好。使用Onyx血管内栓塞治疗目前巳是国内外治疗大型脑AVMW或缺的重雖施之一。

Stroke:未破裂脑动静脉畸形!

在uBAVM试验中,单独进行Onyx栓塞或联合立体定向放射治疗取得了较高的闭塞率。发病率仍然是一个挑战,即使它似乎比ARUBA试验中要低。